From metabolism to disease: Mitochondria's hidden signaling networks unveiled

The structural and functional characteristics of mitochondria shape their role as signaling organelles, with far-reaching ...

Continuous Operations Explained: Benefits, Drawbacks, and Real-world Examples

Discover the meaning of continuous operations, their advantages, disadvantages, and real-life applications to maintain ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
Investing

Omeros stock soars after FDA approves first treatment for TA-TMA

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Morningstar

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...